Table 3.

The evolution of endovascular management for acute complicated Type III aortic dissection

Author	Publication Year	Sample Size	Study Length	Follow up	All cause mortality	Findings / Conclusions	Stent Type
Slonim42	1996	11	1992–1995	Mean: 10.1 months (2 weeks-39 months)	9.1%	Technique included fenestration and stent placement, 2 of 5 fenestration patients required re-intervention	Palmaz®1
Dake43	1999	22	1996–1998	Mean: 13 months	16% (30D)	False lumen thrombosis 79%; Re- vascularization in 76%	Custom
Nienaber44	1999	12	1997–1998	12 months	0.0%	Technical success in 100%; no endoleak; no morbidity	Talent™2
Tiesenhausen45	2001	4	1998	Mean: 11.5 months (2–34 months)	0.0%	False lumen thrombosis 100%; Distal aneurysm in 1 patient	Talent™2
Lopera46	2003	10	1999–2001	Mean: 20 months (7–30 months)	10.0%	Technical failure, stroke, deep vein thrombosis in 1 patient each; False lumen thrombosis 60%; Distal aneurysm in 20%	Custom
Vedantham77	2003	11	1998–2002	Mean: 16 months	0.0%	Preferred to open surgery in complicated Type B aortic dissection	Wallstent®3
Duebener78	2004	10	2000–2003	Mean: 25 months (1–38 months)	20% (30D)	Early mortality reduced by emergency endovascular stent grafting (No morality in follow-up period)	Talent™2
Dialetto47	2005	28	1999–2004	Mean: 18.1 months (1–61 months)	10.7%	Endoleak in 1 patient; False lumen thrombosis 75%; Distal aneurysm 3.5%	Talent™2, Gore EXCLUDER®4
Resch48	2006	115	1994–2005	Median: 14 months (1–79 months)	9.3% (30D)	False lumen thrombosis in 80%; Distal aneurysm in 16%	Talent™2, Gore EXCLUDER®4 Gore TAG®4, Zenith®5 Endofit™6
Chemelli-Steingruber79	2008	38	1996–2008	Mean: 33 months	23.7%	Secondary interventions in 2 patients; Conversion open in 3 patients; Endoleak in 9 patients	Talent™2, Gore EXCLUDER®4 Gore TAG®4
Pearce80	2008	15	2005–2007	Mean: 5.8 months (0–12 months)	13.3% (30D), 20%	TEVAR has high technical success, excellent results at resolving malperfusion, acceptably low complications	Gore TAG®4
Szeto49	2008	35	2004–2007	Mean: 13 months (3–47 months)	2.8%	Technical success 97.1%; 93.4% (1- year survival)	Talent™2, Gore TAG®4 Zenith ELSE®5
Verhoye50	2008	16	1996–2004	12 months	25% (30D)	Distal aorta dilation 1 patient; Freedom from treatment failure at 5 years 67%	Custom, Gore EXCLUDER®4 Gore TAG®4
Feezor81	2009	33	2005–2007	Mean: 5.5 months	21% (30D)	1 major complication in 76% patients, mean follow-up 61% alive and 45% living at home	Gore TAG®4
Albors82	2009	25	2003–2008	Mean: 30 months (7–53 months)	8% (30D)	Type 1 Endoleak in 16%; paraparesis in 4%	Talent™2, Gore TAG®4 Zenith TX1®5, Zenith TX2®5
Khoynezhad28	2009	28	1999–2007	Mean: 36 months (1–88 months)	10.7%	82% (1-year survival); 78% (5 year survival); complete thrombosis 85%; treatment failure 18%	Talent™2, Gore TAG®4
Manning51	2009	52	2001–2008	Mean: 31 months	11.0%	1 patient with persistent false lumen perfusion, only Type IIIb needed re- intervention	Talent™2, Gore TAG®4 Zenith®5, Endofit™6, Relay™7
Patel56	2009	69	1997–2008	Mean: 41.9 months	17.4% (30D), 30%	Freedom from aortic rupture or open repair at 1, 5, and 8 years was 80.2%, 67.7%, and 54.2%	Wallstent®3
Park83	2009	17	1996–2007	Mean: 731 days (3–2719 days)	8.3% (30D)	Malperfusion improved in 90%; Annual growth rate 3.64mm/year thoracic aorta, 2.64mm/year celiac axis, 1.42mm/year infrarenal aorta	Niti-S™8, Wallstent®3 Smart® Stent9

¹Cordis Corporation, Johnson & Johnson Inc., Warren, NJ

²World Medical, Medtronic Vascular Inc., Sunrise, FL

³Boston Scientific Corp., Natick, MA

⁴Thoracic Endoprosthesis, W.L. Gore & Associates, Sunnyvale, CA

⁵Cook Inc,. Bloomington, IN

⁶Endomed Inc., London, United Kingdom

⁷Bolton Medical Inc., Sunrise, FL

⁸Taewoong Medical Co. Ltd., Seoul, Korea

⁹Cordis Corp., Miami Lakes, FL